#USA #New York #Faruqi & Faruqi #PMI #Picard Medical

Faruqi & Faruqi, LLP Reminds Investors of Important Class Action Deadline

Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against Picard Medical, Inc. (NYSE: PMI) in light of significant allegations of misconduct involving the company. Investors who acquired Picard Medical securities between September 2, 2025, and October 31, 2025, should pay close attention to the deadline for leading a federal securities class action lawsuit, which is set for April 13, 2026.

This critical issue was announced in a press release dated March 29, 2026, highlighting the firm’s commitment to protecting the rights of investors who have suffered losses due to alleged fraudulent practices by Picard Medical.

Allegations Against Picard Medical

The investigation into Picard Medical centers around accusations that the company and its executives violated federal securities laws. Specifically, it is alleged that they made false or misleading statements, as well as failed to disclose material facts about the company’s operations.

The key allegations are as follows:

• - The company was involved in a fraudulent stock promotion scheme that utilized misinformation spread on social media platforms.
• - Company insiders and/or affiliates allegedly used offshore or nominee accounts to manipulate the market by dumping shares following a period of artificially inflated stock prices.
• - Public statements made by Picard Medical failed to mention the existence of these fraudulent rumors and the artificial trading activity that impacted the company's stock price.

On October 24, 2025, the stock price of Picard Medical plummeted, closing at $5.31, down from $13.20 just a day earlier. This drastic decline represents approximately a 59.8% loss in value in a single trading session. Such a fall is one of the largest seen since the company's recent initial public offering (IPO).

Participation Options for Investors

Faruqi & Faruqi emphasizes the importance of the lead plaintiff role in the lawsuit. The lead plaintiff is typically the individual or entity with the largest financial interest in the case, and they play a critical role in overseeing the litigation on behalf of all affected investors.

Investors wishing to serve as lead plaintiff must act quickly, as they can submit their motion through legal counsel of their choice, or alternatively, they can opt to remain an absent class member without affecting their ability to recover from any eventual settlement. Notably, all members of the putative class can share in any recovery, regardless of whether they choose to take on the lead plaintiff role or not.

Furthermore, Faruqi & Faruqi LLP encourages anyone with relevant information about Picard Medical's practices—including whistleblowers, former employees, and shareholders—to reach out to them. The firm is dedicated to ensuring that any grievances are addressed and that justice is pursued on behalf of the affected investors.

Next Steps for Affected Investors

For those impacted by the situation at Picard Medical, it is crucial to seek legal advice promptly to understand the available options. Investors can contact Faruqi & Faruqi, LLP directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information on the class action lawsuit or to discuss their particular case in confidentiality.

To stay updated on this developing story, investors are encouraged to follow the firm on LinkedIn, Twitter, or Facebook.

Faruqi & Faruqi, LLP has a long history of advocating for investors’ rights and has successfully recovered millions in settlements since its establishment in 1995. Investors looking to join the class action have until April 13, 2026, to act.

For more information, you can visit Faruqi & Faruqi's website or check out the dedicated page for Picard Medical at www.faruqilaw.com/PMI.

Attorney Advertising: The law firm involved in this matter is Faruqi & Faruqi, LLP, and prior results do not guarantee a similar outcome in any future cases.